天美传媒

Abstract

A malignancy called metaplastic breast cancer (MBC) is defined by the presence of two or more cellular types in its histology, typically a mixture of epithelial and mesenchymal cells. In comparison to invasive ductal carcinoma (IDC), MBC is uncommon, accounting for less than 1% of all breast malignancies. Other than having a lower frequency of lymph node metastases, MBC tumours have worse prognostic characteristics than IDC tumours. The best MBC therapy paradigm is unknown because of its low prevalence and pathological diversity. MBC has been regarded as a variation of IDC due to its rarity. Patients with MBC, however, had inferior outcomes while receiving comparable treatment plans. Recent studies have concentrated on the biological distinctions between MBC and IDC as well as potential new chemotherapeutic drug targets. This essay provides as a summary of recent research on methods for treating MBC patients in a multidisciplinary manner.

Cancer treatment, which uses a multidisciplinary approach and carefully takes into account each patient’s unique needs and preferences, begins with cancer diagnosis. Although screening tests are a crucial tool for cancer early detection, they can have some drawbacks. As opposed to treatment alternatives, which are based on the kind and stage of cancer as well as the patient’s general health, diagnostic tests provide conclusive information regarding the presence of cancer and its characteristics. Commonly utilised treatment modalities include surgery, radiation therapy, chemotherapy, and immunotherapy, either separately or in combination. For the best patient outcomes, it’s crucial to continue monitoring cancer after treatment to look for any indications of recurrence or the development of new tumours. An overview of the significance of cancer diagnosis, screening and diagnostic procedures, available therapies, and monitoring is provided in this review article.